Download PDF
Thromb Haemost 2016; 115(06): 1234-1236
DOI: 10.1160/TH15-11-0902
Letters to the Editor
Schattauer GmbH

Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy

Jan Beyer-Westendorf
1   Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Franziska Michalski
1   Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Luise Tittl
1   Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Susann Hauswald-Dörschel
1   Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Sandra Marten
1   Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
› Author Affiliations
Further Information

Publication History

Received: 24 November 2015

Accepted after major revision: 17 February 2016

Publication Date:
27 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Ferreira M, Barsam S, Patel JP. et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol. 2015 Epub ahead of print.
    PubMedSearch in Google Scholar
  • 2 De Crem N, Peerlinck K, Vanassche T. et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015 Epub ahead of print.
    PubMedSearch in Google Scholar
  • 3 Martinelli I, Lensing AW, Middeldorp S. et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2015 Epub ahead of print.
    PubMedSearch in Google Scholar
  • 4 Beyer-Westendorf J, Gelbricht V, Forster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896.
    CrossrefPubMedSearch in Google Scholar
  • 5 Beyer-Westendorf J, Gelbricht V, Forster K. et al. Safety of switching from Vitamin-K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. Br J Clin Pharmacol. 2014 Epub ahead of print.
    PubMedSearch in Google Scholar
  • 6 Beyer-Westendorf J, Forster K, Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
    CrossrefPubMedSearch in Google Scholar
  • 7 Beyer-Westendorf J, Ebertz F, Forster K. et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247-1257.
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Michalski F, Tittl L, Werth S. et al. Selection, management, and outcome of vitamin K antagonisttreated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015; 114: 1076-1084.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
    CrossrefPubMedSearch in Google Scholar